These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 14608585)

  • 1. CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42.
    Andreasen N; Sjögren M; Blennow K
    World J Biol Psychiatry; 2003 Oct; 4(4):147-55. PubMed ID: 14608585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry.
    Blennow K; Vanmechelen E
    Brain Res Bull; 2003 Aug; 61(3):235-42. PubMed ID: 12909293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment.
    Andreasen N; Vanmechelen E; Vanderstichele H; Davidsson P; Blennow K
    Acta Neurol Scand Suppl; 2003; 179():47-51. PubMed ID: 12603251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers.
    Sjögren M; Andreasen N; Blennow K
    Clin Chim Acta; 2003 Jun; 332(1-2):1-10. PubMed ID: 12763273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.
    Andreasen N; Minthon L; Davidsson P; Vanmechelen E; Vanderstichele H; Winblad B; Blennow K
    Arch Neurol; 2001 Mar; 58(3):373-9. PubMed ID: 11255440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid biomarkers for Alzheimer's disease: current limitations and recent developments.
    Zetterberg H
    Curr Opin Psychiatry; 2015 Sep; 28(5):402-9. PubMed ID: 26147615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.
    Galasko D; Chang L; Motter R; Clark CM; Kaye J; Knopman D; Thomas R; Kholodenko D; Schenk D; Lieberburg I; Miller B; Green R; Basherad R; Kertiles L; Boss MA; Seubert P
    Arch Neurol; 1998 Jul; 55(7):937-45. PubMed ID: 9678311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
    Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
    J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF tau protein and beta-amyloid (1-42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population.
    Kapaki E; Paraskevas GP; Zalonis I; Zournas C
    Eur J Neurol; 2003 Mar; 10(2):119-28. PubMed ID: 12603286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease.
    Blennow K; Vanmechelen E; Hampel H
    Mol Neurobiol; 2001; 24(1-3):87-97. PubMed ID: 11831556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
    Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
    J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
    Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
    Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
    Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
    Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols.
    Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Giau VV; Bagyinszky E; Lim KT; Kang SM; An SS; Park YH; Youn YC; Kim S
    J Alzheimers Dis; 2016 May; 52(4):1403-13. PubMed ID: 27163824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomic analysis of cerebrospinal fluid in Alzheimer's disease: wanted dead or alive.
    Oláh Z; Kálmán J; Tóth ME; Zvara Á; Sántha M; Ivitz E; Janka Z; Pákáski M
    J Alzheimers Dis; 2015; 44(4):1303-12. PubMed ID: 25428253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease.
    Valcárcel-Nazco C; Perestelo-Pérez L; Molinuevo JL; Mar J; Castilla I; Serrano-Aguilar P
    J Alzheimers Dis; 2014; 42(3):777-88. PubMed ID: 24916543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
    Mattsson N; Zetterberg H; Hansson O; Andreasen N; Parnetti L; Jonsson M; Herukka SK; van der Flier WM; Blankenstein MA; Ewers M; Rich K; Kaiser E; Verbeek M; Tsolaki M; Mulugeta E; Rosén E; Aarsland D; Visser PJ; Schröder J; Marcusson J; de Leon M; Hampel H; Scheltens P; Pirttilä T; Wallin A; Jönhagen ME; Minthon L; Winblad B; Blennow K
    JAMA; 2009 Jul; 302(4):385-93. PubMed ID: 19622817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.